| Neural induction, the default model and embryonic stem cells I Muñoz-Sanjuán, AH Brivanlou Nature Reviews Neuroscience 3 (4), 271-280, 2002 | 750 | 2002 |
| Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. PM Smallwood, I Munoz-Sanjuan, P Tong, JP Macke, SH Hendry, ... Proceedings of the National Academy of Sciences 93 (18), 9850-9857, 1996 | 485 | 1996 |
| Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease T Heikkinen, K Lehtimäki, N Vartiainen, J Puoliväli, SJ Hendricks, ... PloS one 7 (12), e50717, 2012 | 265 | 2012 |
| Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications JG Bilsland, A Wheeldon, A Mead, P Znamenskiy, S Almond, KA Waters, ... Neuropsychopharmacology 33 (3), 685-700, 2008 | 230 | 2008 |
| Human glia can both induce and rescue aspects of disease phenotype in Huntington disease A Benraiss, S Wang, S Herrlinger, X Li, D Chandler-Militello, J Mauceri, ... Nature communications 7 (1), 11758, 2016 | 195 | 2016 |
| Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease B Zeitler, S Froelich, K Marlen, DA Shivak, Q Yu, D Li, JR Pearl, JC Miller, ... Nature medicine 25 (7), 1131-1142, 2019 | 191 | 2019 |
| Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities SJ Tabrizi, C Estevez-Fraga, WMC van Roon-Mom, MD Flower, RI Scahill, ... The Lancet Neurology 21 (7), 645-658, 2022 | 190 | 2022 |
| Unravelling and exploiting astrocyte dysfunction in Huntington’s disease BS Khakh, V Beaumont, R Cachope, I Munoz-Sanjuan, SA Goldman, ... Trends in neurosciences 40 (7), 422-437, 2017 | 189 | 2017 |
| Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington’s disease RW Bürli, CA Luckhurst, O Aziz, KL Matthews, D Yates, KA Lyons, ... Journal of medicinal chemistry 56 (24), 9934-9954, 2013 | 178 | 2013 |
| Cell fate specification and competence by Coco, a maternal BMP, TGFβand Wnt inhibitor E Bell, I Muñoz-Sanjuán, CR Altmann, A Vonica, AH Brivanlou Oxford University Press for The Company of Biologists Limited 130 (7), 1381-1389, 2003 | 174 | 2003 |
| Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington’s disease XH Lu, VB Mattis, N Wang, I Al-Ramahi, N van den Berg, SA Fratantoni, ... Science translational medicine 6 (268), 268ra178-268ra178, 2014 | 141 | 2014 |
| The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease I Munoz-Sanjuan, GP Bates The Journal of clinical investigation 121 (2), 476-483, 2011 | 129 | 2011 |
| Isoform diversity among fibroblast growth factor homologous factors is generated by alternative promoter usage and differential splicing I Munoz-Sanjuan, PM Smallwood, J Nathans Journal of Biological Chemistry 275 (4), 2589-2597, 2000 | 129 | 2000 |
| Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington’s disease models V Beaumont, S Zhong, H Lin, WJ Xu, A Bradaia, E Steidl, M Gleyzes, ... Neuron 92 (6), 1220-1237, 2016 | 108 | 2016 |
| A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington’s disease D Todd, I Gowers, SJ Dowler, MD Wall, G McAllister, DF Fischer, ... PloS one 9 (2), e87923, 2014 | 94 | 2014 |
| Discovery and structure–activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington’s disease ME Prime, OA Andersen, JJ Barker, MA Brooks, RKY Cheng, ... Journal of medicinal chemistry 55 (3), 1021-1046, 2012 | 94 | 2012 |
| A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors S Schaertl, M Prime, J Wityak, C Dominguez, I Munoz-Sanjuan, ... Journal of biomolecular screening 15 (5), 478-487, 2010 | 93 | 2010 |
| Characterization of HTT Inclusion Size, Location, and Timing in the zQ175 Mouse Model of Huntington´s Disease: An In Vivo High-Content Imaging Study N Carty, N Berson, K Tillack, C Thiede, D Scholz, K Kottig, Y Sedaghat, ... PloS one 10 (4), e0123527, 2015 | 80 | 2015 |
| Pharmacokinetics of memantine in rats and mice MG Beconi, D Howland, L Park, K Lyons, J Giuliano, C Dominguez, ... PLoS Currents 3, 2011 | 79 | 2011 |
| Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington’s disease LM Toledo-Sherman, ME Prime, L Mrzljak, MG Beconi, A Beresford, ... Journal of medicinal chemistry 58 (3), 1159-1183, 2015 | 72 | 2015 |
